Most Read Articles
04 Dec 2017
The use of atropine appears to prevent myopic progression, as supported by level I evidence, according to a recent study. Additionally, myopic rebound has been reported after treatment discontinuation, but this is minimized by using low doses, particularly atropine 0.01%.
Jairia Dela Cruz, 01 Jan 2018
Individuals with diabetic retinopathy (DR) appear to have thicker macula and outer retina compared with those who do not have the diabetic eye disease, and such thickening is more pronounced in eyes with severe DR, according to a study.
Roshini Claire Anthony, 30 Nov 2017

Individuals with mild-to-moderate non-proliferative diabetic retinopathy appear to have an elevated risk of falls compared with individuals with diabetes but no diabetic retinopathy, according to a Singapore study.

Jairia Dela Cruz, 03 Jan 2018
Fingerprick autologous blood (FAB) appears to be effective and safe in the treatment of severe dry eye syndrome (DES), eliminating the need for blood donation and specialist processing, as reported in a pilot study.

IVZ therapy increases treatment-free interval in nonresponsive eyes with nAMD

27 Dec 2017

Use of intravitreal ziv-aflibercept (IVZ) therapy improves treatment-free interval in eyes with neovascular age-related macular degeneration (nAMD) that are nonresponsive to bevacizumab and ranibizumab, a recent study has shown. However, no significant change in visual and anatomic outcomes has been observed.

IVZ therapy provided no change in the mean logarithm of minimum angle of resolution (logMAR) best corrected visual acuity (BCVA) at baseline and following treatment (p=0.978). Mean IVZ injections during 12 months was 5.9±3.3, and the mean number of antivascular endothelial growth factors (VEGFs) injections prior to switching to IVZ was 8.4±4.7.

Mean treatment-free interval was longer during IVZ therapy compared with days prior to IVZ therapy (114.4±67.1 vs 76.3±54.6 days; p=0.03). Visual gains of at least 0.1 logMAR were achieved in five eyes (31.25 percent), while three eyes (18.75 percent) had stable BCVA (within 0.1 logMAR) and eight eyes (50 percent) had BCVA decline of at least 0.1 logMAR.

Mean changes in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, and presence of subretinal (SRF) and intraretinal fluid (IRF) were not significant at 12 months vs baseline. Additionally, there were no adverse events reported.

Researchers included 16 eyes of 14 patients with nAMD who were on prior treatment with bevacizumab and ranibizumab in this retrospective study. All eyes were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months.

The mean change in BCVA was the primary outcome measure, and secondary outcome measures included mean change in CMT, RPED heights, longest treatment-free interval, presence of SRF and IRF, and adverse events.

Editor's Recommendations
Most Read Articles
04 Dec 2017
The use of atropine appears to prevent myopic progression, as supported by level I evidence, according to a recent study. Additionally, myopic rebound has been reported after treatment discontinuation, but this is minimized by using low doses, particularly atropine 0.01%.
Jairia Dela Cruz, 01 Jan 2018
Individuals with diabetic retinopathy (DR) appear to have thicker macula and outer retina compared with those who do not have the diabetic eye disease, and such thickening is more pronounced in eyes with severe DR, according to a study.
Roshini Claire Anthony, 30 Nov 2017

Individuals with mild-to-moderate non-proliferative diabetic retinopathy appear to have an elevated risk of falls compared with individuals with diabetes but no diabetic retinopathy, according to a Singapore study.

Jairia Dela Cruz, 03 Jan 2018
Fingerprick autologous blood (FAB) appears to be effective and safe in the treatment of severe dry eye syndrome (DES), eliminating the need for blood donation and specialist processing, as reported in a pilot study.